Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy

AIDS Patient Care and STDs

Volumn 21, Issue 2, 2007, Pages 92-99

  Quiros Roldan, Eugenia ^a   Torti, Carlo ^a,h   Lapadula, Giuseppe ^a   Ladisa, Nicoletta ^b   Micheli, Valeria ^c   Patroni, Andrea ^a   Cusato, Maria ^d   Pierotti, Piera ^e   Tirelli, Valeria ^a   Uccelli, Maria Cristina ^a   Di Giambenedetto, Simona ^f   Castelnuovo, Filippo ^g   Gargiulo, Franco ^a   Manca, Nino ^a   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g Spedali Civili of Brescia ^*  (Italy)

^h Institute of Infectious and Tropical Diseases   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PREDICTION; PROTEINASE INHIBITION; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; SALVAGE THERAPY; VIRAL LOAD;

EID: 33847794008     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.0037     Document Type: Article

References (15)

1. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologie and immunologic response. California Collaborative Treatment Group. AIDS 1999;13:1099-1107.
2. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
3. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002; 16:369-379.
4. Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006;41:315-322.
5. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000;14:1333-1339.
6. Baxter JD, Merigan TC, Wentworth DN, et al. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002;16:1131-1138.
7. Mallon PW, Ray J, Cooper DA. Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 2003; 26:223-227.
8. Yasuda JM, Miller C, Currier JS, et al. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther 2004;9:753-761.
9. Duval X, Mentre F, Lamotte C, et al. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. Ther Drug Monit 2005;27:63-70.
10. Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: The Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis 2005;40: 1828-1836.
11. Antinori A, Cozzi-Lepri A, Ammassari A, et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004;9:291-296.
12. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75.
13. Villani P, Feroggio M, Gianelli L, et al. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay. Ther Drug Monit 2001;23:380-388.
14. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. www.AIDSinfo.nih.gov (Last accessed May 4, 2006).
15. Boffito M, Arnaudo I, Raiteri R, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: Pharmacokinetics and pharmacodynamics. AIDS 2002;16: 2081-2083.